PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

Biotechnology & Medical Research

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.95 ^EUR	0.00%		+1.03%	-35.87%

Apr. 15	Phaxiam initiates trial in infective endocarditis	CF
Apr. 15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

March 20, 2024 at 01:00 pm EDT

PHAXIAM Therapeutics S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was EUR 1.33 million compared to EUR 31 million a year ago. Net loss was EUR 23.49 million compared to EUR 0.227 million a year ago.

Latest news about PHAXIAM Therapeutics S.A.

Phaxiam initiates trial in infective endocarditis	Apr. 15	CF
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	Apr. 15	CI
Transcript : PHAXIAM Therapeutics S.A., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
PHAXIAM Therapeutics Completes Delisting of ADS From Nasdaq	Mar. 11	MT
Phaxiam Therapeutics Delists from Nasdaq Capital Market	Mar. 11	MT
PHAXIAM Therapeutics S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index	Mar. 07	CI
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	Mar. 05	DJ
ADRs Slump; Jianpu Technology Declines 62%	Feb. 21	DJ
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	Feb. 21
Phaxiam to delist ADS from Nasdaq in March	Feb. 21	CF
PHAXIAM Therapeutics S.A.(NasdaqCM:PHXM) added to NASDAQ Composite Index	23-06-29	CI

Chart PHAXIAM Therapeutics S.A.

Duration

Period

More charts

Company Profile

PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.95 EUR

Average target price

6.85 EUR

Spread / Average Target

+132.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHAXIAM THERAPEUTICS S.A.	-35.87%	19.13M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs